Hematologic Oncology | Specialty

The Current Unmet Needs in PTCL Treatment and Prospects

January 28th 2019

PTCL Treatment in the Community Setting

January 28th 2019

The Impact of Brentuximab Vedotin as PTCL Treatment

January 28th 2019

Treating Patients With CD30-Positive PTCL

January 28th 2019

An Overview of Peripheral T-Cell Lymphoma

January 28th 2019

PTCL Community Treatment and Future Advancements

January 28th 2019

The ECHELON-2 Trial Presented at ASH 2018

January 28th 2019

Brentuximab Vedotin Overview and Treatment Advice

January 28th 2019

T-Cell Lymphoma Differential Diagnosis and CD30 Treatment

January 28th 2019

Peripheral T-Cell Lymphoma Classifications and CD30 Testing

January 28th 2019

Dr. Oh Discusses the Differences Between Investigational JAK Inhibitors and Ruxolitinib in MPNs

January 26th 2019

Stephen Oh, MD, PhD, assistant professor of medicine, Division of Hematology, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the differences between investigational JAK inhibitors and ruxolitinib (Jakafi) in the treatment of patients with myeloproliferative neoplasms (MPNs).

Blood Cancers Associated With Higher Treatment and Out-of-Pocket Costs

January 25th 2019

Patients with blood cancers face greater treatment costs than those with solid tumors. Furthermore, healthcare spending for these patients is already higher than average before diagnosis and does not return to prediagnosis levels even after successful treatment.

The Future of ITP Treatment

January 24th 2019

Rituximab and Salvage Therapies for Patients With ITP

January 24th 2019

TPO Duration of Response and Toxicity

January 24th 2019

TPO Receptor Agonist Selection and Patient Adherence

January 24th 2019

Romiplostim Classification and Mechanism of Action

January 24th 2019

Fostamatinib as Second-Line ITP Therapy

January 24th 2019

Second-Line Treatment Options for Patients with ITP

January 24th 2019

Steroid Combination Therapy & New ASH Guidelines

January 24th 2019